Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa

Table 1 Change in outcomes for ITT and completer samples during 8-weeks of lisdexamfetamine dimesylate treatment

Measure	Intent-to-treat sample (n = 23)					Study completers (n = 19)
	Baseline		Post or LOCF		Cohen’s d	Baseline		Post		Cohen’s d
	M	SD	M	SD		M	SD	M	SD	Cohen’s d
Hunger and cognitive restraint
TFEQ restraint	12.52	5.26	10.57	4.99	0.38	12.47	5.33	9.68	4.57	0.56
TFEQ hunger	8.22	3.81	3.96	3.69	1.14	8.00	3.87	3.42	3.72	1.21
Impulsivity
TFEQ disinhibition	12.74	2.49	6.26	4.27	1.85	12.74	2.57	5.16	3.67	2.31
BIS-11 total	65.26	8.80	63.87	11.61	0.13	65.11	7.89	62.84	11.12	0.24
BIS-11 attention	17.83	4.42	17.48	4.61	0.08	17.58	4.44	17.12	4.40	0.10
BIS-11 motor	23.04	3.87	22.52	4.09	0.13	23.00	3.51	22.16	4.03	0.22
BIS-11 NP	24.39	3.86	23.87	4.66	0.12	24.53	3.64	23.58	4.39	0.24
Obsessive compulsive features
YBOCS-BE total	22.30	3.42	5.83	4.33	4.22	22.63	2.99	4.89	3.60	5.36
YBOCS-BE (O)	10.97	1.62	3.52	2.78	3.27	11.00	1.41	2.68	2.06	4.71
YBOCS-BE (C)	11.39	2.04	2.65	2.23	4.09	11.63	1.86	2.21	1.99	4.89
Eating disorder psychopathology and impairment
EDE restraint	1.76	1.41	0.97	1.27	0.59	1.53	1.38	0.58	0.91	0.81
EDE eating concern	2.23	1.28	1.03	1.26	0.94	2.01	1.25	0.57	0.68	1.43
EDE shape concern	3.48	1.66	2.06	1.67	0.85	3.19	1.67	1.47	1.09	1.22
EDE weight concern	2.79	1.56	1.63	1.40	0.78	2.57	1.61	1.16	0.99	1.06
EDE global score	2.56	1.29	1.42	1.27	0.89	2.32	1.26	0.94	0.69	1.36
CIA	32.42	8.04	13.04	12.17	1.88	31.72	7.76	9.00	8.15	2.86

Cohen’s d reflects differences between baseline and post or LOCF measurements
TFEQ Three factor eating questionnaire, YBOCS-BE Yale Brown obsessive compulsive scale (modified for binge eating), O obsessions, C compulsions), BIS-11 Barratt impulsiveness scale, NP non-planning, EDE eating disorder examination, CIA clinical impairment assessment

ISSN: 2050-2974